Sareum (SAR) Share Price, News & Analysis

Company Overview

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com

Key Stats

• Today's Range: 16.60 to 18
• 50-Day Range: 16.94 to 27.35
• 52-Week Range: 10 to 52.50
• Volume: 126,721 shs
• Average Volume: 157,502 shs
• Market Capitalization: £21.16 million
• P/E Ratio: N/A
• Dividend Yield: 1.10%
• Price Target: N/A
• Consensus Rating: N/A

SAR Stock Analysis - Frequently Asked Questions

How have SAR shares performed this year?

Sareum's stock was trading at GBX 24.60 on January 1st, 2025. Since then, SAR shares have decreased by 31.1% and is now trading at GBX 16.94.
View the best growth stocks for 2025 here.

How were Sareum's earnings last quarter?

Sareum Holdings plc (LON:SAR) released its quarterly earnings data on Tuesday, October, 29th. The company reported ($4.20) earnings per share (EPS) for the quarter.

How do I buy shares of Sareum?

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Sareum own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Sierra Oncology (SRRA), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Summit Therapeutics (SMMT).

Company Calendar

• Last Earnings: 10/29/2024
• Today: 2/21/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Financial Services
• Current Symbol: LON:SAR
• CUSIP: N/A
• CIK: N/A
• Web: www.sareum.co.uk
• Phone: +44-1223-497700
• Fax: N/A
• Employees: 3,211
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (4.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-5,275,221.97
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -270.25%
• Return on Assets: -113.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.22
• Quick Ratio: 10.37

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 1.50 per share
• Price / Cash Flow: 11.32
• Book Value: GBX 2.61 per share
• Price / Book: 6.49

Miscellaneous

• Outstanding Shares: 124,928,001
• Free Float: N/A
• Market Cap: £21.16 million
• Optionable: Not Optionable
• Beta: -1.08